Cancer Therapy

Photodynamic Therapy

Tumor Targeted Photosensitizers

Long Wavelength Photosensitizers

Imaging & Therapy

PET / Fluorescence





Related Publications


The development of multifunctional agents, which have the capability of using two or more imaging techniques that are complimentary to each other and can also be combined with a treatment modality, has great potential for significantly improving the outcome of patient treatment. The three critical components of image-guided therapy are navigation, control and monitoring the therapy delivery. They all rely on the target identification—precise navigation requires clear identification of the target, to monitor treatment delivery, the target lesions and all adjacent tissues must be identified accurately while controlling the intervention of procedure.

Compared to a free photosensitizer (PS), the corresponding polyacrylamide-based nanoformulation showed a remarkable in vivo enhancement in tumor-imaging and photodynamic therapy. The non-toxic nanoparticles (30-35 nm) formulation drastically changed the pharmacokinetic profile of the imaging/therapeutic agent (formulated in 1% Tween 80 and 5%/D5W) with remarkable enhancement in tumor uptake (10% of the injected dose) and reduced uptake in spleen and liver. The labeled (124I-) and non-labeled PS in combination showed great potential for tumor imaging (PET/fluorescence) and photodynamic therapy in BALB/c mice bearing Colon26 tumors and provides an opportunity for a “See and Treat” approach.

Among the photosensitizers evaluated so far, the porphyrin-based compounds have shown a great potential in clinic or at advanced preclinical studies.

Whole body PET Images of BALB/c mice bearing subcutaneous Colon26 tumors on the right shoulder with (A) 124I-PS2 at 24, 48, and 72 h post-injection (i.v.); (B) 124I-PS2 post-loaded in NPs (NP2 – 1.4 mg NPs per mouse) at 24, 48, and 72 h post-injection (i.v.); (C) 124I-PS2 post-loaded in NPs (NP2–0.05 mg NPs per mouse) at 24, 48, and 72 h post-injection (i.v.); and (D) the relative uptake values (RUV) of PS2 and NP2 (1.4 mg and 0.05 mg NPs per mouse). Whole-body fluorescence reflectance images of BALB/c mice bearing subcutaneous Colon26 tumors. (E-G) PS1; (H-J) NP1 (10 mg of NPs per ml) at 24, 48, and 72 h post-injection (i.v.). In the case just mention that excitation wavelength = 665 nm and emission wavelength = 720 nm (instead of 700 nm).